

Outcome Capital Life Sciences Market Pulse November 2021





Strategic Transactional Insights & Market Trends



Outcome Capital At A Glance...

Outcome Capital is a highly-specialized life sciences advisory & investment banking firm providing middle-market transactional expertise underpinned by a value-added, market-aligned approach to strategy execution. Our industrydedicated specialists leverage significant operational, strategic & scientific knowledge in sharing their insights on industry-defining transactions.

Life Science Verticals:

MedTech Pharma

- Diagnostics
- Life Sciences Services
- Biotech
- Digital Health)

Transaction Focus:

- M&A
- Management **Buyouts & Roll-Ups**
- Partnerina Equity Financings
 - Regulatory
 - Reimbursement

Scientific

- **Expertise Across the Value Chain:**
 - Legal & IP
 - Operational
 - Transactional >

Outcome Capital Pulse: Monthly Insights of Life Science Deal Action & Drivers

Highlighted Transactions

Strategic analysis from Outcome Capital's life sciences-dedicated deal team

Transaction Lineup

Snapshot of noteworthy life sciences deals highlighting industry-defining activity

Outcome Index Tracker

Custom medtech, biotech/pharma, diagnostics & services indices benchmarked to the S&P500



Highlighted Transactions



In a strategic move to augment its synthetic biology capabilities by adding animal-based discovery, Twist will move downstream beyond being a service provider toward an internal antibody generation effort. With Abveris' animal-based antibody discovery platform, Twist will have multiple approaches offering a comprehensive antibody discovery and optimization capability as well as broadened pharma relationships.



Oded Ben-Joseph, PhD, MBA Managing Director Outcome Capital, LLC oben-joseph@outcomecapital.com

Novo Nordisk's Prior Investment Supports Dicerna's Premium Value






The Novo Nordisk CEO, Lars Fruergaard Jørgensen, landed the major takeover of Dicerna. Novo Nordisk agreed to a \$3.2 billion buyout of its RNAi partner, Dicerna Pharmaceuticals, as part of its search for new growth drivers, offering an 80% premium over the closing price of Dicerna. The Danish drug maker partnered with Dicerna in 2019, paying \$175 million upfront and committing to pay \$25 million at the end of each of the first three years of the collaboration, plus up to \$357.5 million in milestones. The relationship gave Novo Nordisk a close look at Dicerna. Both the recent successes of RNA-based COVID-19 vaccines and Novo's financial commitments to the existent partnership supported the premium on acquisition. A great return for Dicerna shareholders.



Ellen Baron, PhD Managing Director Outcome Capital, LLC <u>ebaron@outcomecapital.com</u>



Regeneron Links Up With Nykode For Vaccine Expertise



Two years into a global pandemic, interest remains high in all things vaccine, and bio-dollars remain the most stable currency for cross-border transactions. Regeneron's \$925 million transaction with Oslo-based Nykode is comprised of a \$30 million upfront payment, a \$20 million equity investment, and a heavily back-ended \$875 million of contingent milestone payments as well as potential royalties. The collaboration covers multiple targets across five programs, two focused on vaccines against infectious disease and three against cancer. The vaccines will combine Regeneron's antigen selection expertise and VelociSuite models with Nykode's modular vaccine platform and expertise in vaccine design.



Paul Mieyal, PhD, CFA Managing Director Outcome Capital, LLC pmieyal@outcomecapital.com

Novartis Deal Validates Demand For Targeted Protein Degraders



 DUNAD
therapeutics
 \$1.3B
 \$0 NOVARTIS

 Target
 Deal Size
 Partner

 Novartis has forged a deal with UK-based Dunad Therapeutics to leverage their proprietary platform toward
developing next-generation SMEs as targeted protein degraders. Protein degradation holds the promise of
ender the protein degraders. Protein degradation holds the promise of
protein degradation holds the promise of

developing next-generation SMEs as targeted protein degraders. Protein degradation holds the promise of making normally undruggable targets druggable. Although this approach has been around for a decade when the first targeted protein degrader, proteolysis targeting chimera (PROTAC), was developed, Dunad's approach is different in that it is tunable for any specificity, and Novartis provides the targets for this collaboration. For the rights to apply the platform to up to four targets, Novartis pays equity and \$24M upfront, in addition to up to \$1.3B in milestones – plus royalties. We do not anticipate this to be a one-off deal in the world of targeted protein degradation, but rather a validation of what Roots Analysis projected two years ago to be part of an annualized growth rate in this market of over 30%. It is also a great example of the pioneering type of biotech innovation that we at Outcome Capital are particularly interested in and the type of company that we are well-positioned to help when liquidity events such as Strategic Partnerships are possible.



John Armstrong, PhD Managing Director Outcome Capital, LLC jarmstrong@outcomecapital.com

The Pharma Services Segment Continues To Outpace The Market





BioAgilytix has moved on to their third financial sponsor in eight years, signifying an impressive growth trajectory, in a market that continues to reward their success. BioAgilytix' 2018 transaction was for a mere \$280M. Now, three years later, the estimated \$2.5B transaction with Cinven shows active interest in the pharmaceutical services sectors. Outcome Capital looks forward to watching this tremendously active segment closely.



Craig Steger Senior Vice President Outcome Capital, LLC <u>csteger@outcomecapital.com</u>

OUTCOME CAPITAL | LIFE SCIENCES MARKET PULSE Orthopedics Enters The Digital Age



DePuy Synthes

PART OF THE Common & Common FAMILY OF COMPANIES

Buyer

OrthoSpin Target

On the heels of a 510(k) approval for their second generation, automated, digitally enabled external fixation system, OrthoSpin has been acquired by a leader in the space, DePuy Synthes, J&J's orthopedics franchise. OrthoSpin's history with J&J dates back to 2018, when the Israeli company received Series A financing from JJDC, J&J's strategic venture arm, who also led the company's Series B financing in March 2020. By incorporating digital interfaces and capabilities, OrthoSpin is providing J&J with a highly differentiated technology capturing significant market attention.

80M

Deal Size



Thomas Busby Vice President Outcome Capital, LLC tbusby@outcomecapital.com



Ophthalmology Taps Gene Therapy For New Advances



Since the approval of Luxturna® in 2017, interest in ophthalmology-focused viral gene therapies has accelerated considerably among major strategics. AbbVie's collaboration with REGENXBIO follows multiple acquisitions from the likes of Roche, Novartis, Astellas, Biogen and Janssen. Ophthalmology presents a unique opportunity for gene therapies as the therapy is directed towards a confined physiological compartment (the eye), but setbacks in recent clinical trials have given pause to many in the space. Despite these setbacks, AbbVie continues to expand its eye care business to build on the acquisition of Allergan. The partnership structure of this transaction mitigates risk for AbbVie in their acquisition of RGX-314 (currently in Phase II trials) while also providing AbbVie with access to a novel delivery system for ophthalmology applications.



Nick Frame, PhD Senior Associate Outcome Capital, LLC <u>nframe@outcomecapital.com</u>



November 2021 | Transaction Lineup

November 2021 Transaction Lineup

Release

Date	Target	Buyer/ Investor	Target Description	Deal Type	Deal Value (\$M)	Up-Front Payment (\$M)	Vertical
<u>11/1/21</u>	S PharmaFluidics	ThermoFisher SCIENTIFIC	Developer of micro-chip-based µPAC chromatography columns to enhance biomarker, proteomics and R&D applications.	M&A	Undisclosed	Undisclosed	Diagnostics
<u>11/2/21</u>	DUNAD therapeutics	U NOVARTIS	Strategic collaboration to generate orally bioavailable covalent & protein degrading small molecule drugs using Dunad's platform.	Partnership	1,324	24	Biotech / Pharma
<u>11/3/21</u>	BIOLOGICS		Clinical-stage biopharma company developing novel immunotherapies for cancer & platform enabling intracellular biologics delivery.	Financing	15	N/A	Biotech / Pharma
<u>11/4/21</u>	OrthoSpin	DePuy Synthes	Developer of user-friendly robotic orthopedic device for external circular fixation treatment.	M&A	80	80	MedTech
<u>11/4/21</u>	Platelet Bio . 🔨	Hedthwentures SymBissis Oxford FINANCE	Preclinical biotech company pioneering a new platform of allogeneic cell therapies based on platelet biology for Immune Thrombocytopenia.	Financing	76	N/A	Biotech / Pharma
<u>11/8/21</u>	-I J- Cardiologs [®] Al Serving Cardiology	PHILIPS	Developer of FDA-cleared, AI-based electrocardiogram analysis platform to diagnose atrial fibrillation & other disorders.	M&A	Undisclosed	Undisclosed	MedTech
<u>Hyperlinked</u> <u>to Press</u>	MedTech	Biotech/Ph	arma Digital Health Diagn	ostics	Life Science Tools	Services	10

OUTCOME CAPITAL PULSE

November 2021 Transaction Lineup

Date	Target	Buyer/ Investor	Target Description	Deal Type	Deal Value (\$M)	Up-Front Payment (\$M)	Vertical
<u>11/8/21</u>		Alcon	Developer of novel Hydrus® Microstent designed to lower intraocular pressure for open-angle glaucoma patients.	M&A	475	475	MedTech
<u>11/8/21</u>		Lauront & Benon	Developer of novel, small molecule therapeutics using the world's largest, end- to-end AI drug discovery system.	Financing	40	N/A	Biotech / Pharma
<u>11/9/21</u>	REGENXBIO	abbvie	Collaboration to develop & commercialize a potential one-time gene therapy for the treatment of chronic retinal diseases.	Partnership	1,750	370	Biotech / Pharma
<u>11/10/21</u>		Genentech A Member of the Roche Group	Research collaboration to use Novome's GEMMs platform to develop bacterial strains that express & deliver therapeutic molecules for intestinal diseases.	Partnership	605	15	Biotech / Pharma
<u>11/10/21</u>	generate	CooperSurgical®	Leading provider of donor egg & sperm for fertility treatments, fertility cryopreservation services & newborn stem cell storage.	M&A	1,605	Undisclosed	Services
<u>11/11/21</u>	AppliedVR	F / PRIME /sway ventures	Provider of virtual reality-based treatments combining well-established cognitive behavioral therapies with mindfulness exercises to treat chronic pain.	Financing	36	N/A	Digital Health

Hyperlinked to Press Release

Digital Health

OUTCOME CAPITAL PULSE

November 2021 Transaction Lineup

Date	Target	Buyer/ Investor	Target Description	Deal Type	Deal Value (\$M)	Up-Front Payment (\$M)	Vertical
<u>11/15/21</u>	COMBANGIO	Kala.	Clinical-stage company developing regenerative biotherapies for severe ocular surface diseases.	M&A	126	21	Biotech / Pharma
<u>11/16/21</u>	H E A L T H	AME CLOUD VENTURES Marcania Contraction C	Bioelectronic medicine developer of wearable neuromodulation therapies to deliver individualized peripheral nerve stimulation.	Financing	77	N/A	MedTech
<u>11/16/21</u>	BioAgilytix 🐲	Cinven	Global CRO focused on supporting pharma & biotech partners in all phases of drug development.	M&A	2,500	2,500	Services
<u>11/17/21</u>		Takeda	Collaboration to develop & commercialize an investigational, brain-penetrant progranulin replacement therapy for frontotemporal dementia-granulin,	Partnership	240	150	Biotech / Pharma
<u>11/17/21</u>	Alpheusmedical	National Brain Tumor Society	Developer of novel, non-invasive drug- device sonodynamic platform targeting solid body cancers.	Financing	16	N/A	MedTech
<u>11/18/21</u>		labcorp	Preclinical CRO delivering best-in-class nonclinical <i>in vivo, in vitro</i> & analytical testing services to life sciences companies.	M&A	Undisclosed	Undisclosed	Services



Digital Health

November 2021 Transaction Lineup

Release

Date	Target	Buyer/ Investor	Target Description	Deal Type	Deal Value (\$M)	Up-Front Payment (\$M)	Vertical
<u>11/18/21</u>	Dicerna	novo nordisk [®]	Biopharma company focused on discovering & developing medicines that leverage RNA interference to selectively silence genes.	M&A	3,211	3,211	Biotech / Pharma
<u>11/22/21</u>	以abveris	T W I S T	In vivo antibody discovery service company developing next-generation biologics, cell therapies, vaccines & diagnostics.	M&A	190	150	Services
<u>11/22/21</u>	Vathenahealth	Hellman & Friedman	Provider of cloud-based enterprise software solutions for patient engagement, telehealth, population health & value- based care management.	M&A	17,000	17,000	Digital Health
<u>11/23/21</u>	nykode therapeutics	REGENERON	Collaboration agreement with Regeneron to discover, develop & commercialize new vaccines for cancer & infectious disease.	Partnership	925	50	Biotech / Pharma
<u>11/23/21</u>	Gene If a better beginning:	-	Developer of remote platform allowing access to medical-grade data for pregnancy care management.	IPO	50	N/A	Digital Health
<u>11/29/21</u>		Detter Janus Henderson Polit 72 Syncona & Techna Manager III Syncona & Techna Manager III Construction Syncona & Techna Manager III Construction Con	Developer of engineered T-regulatory cell therapies using phenotype lock technology for serious medical conditions driven by the immune system.	Financing	156	N/A	Biotech / Pharma
<u>Hyperlinked</u> <u>to Press</u>	MedTech	Biotech/Ph	arma Digital Health Diagr	nostics	Life Science Tools	Services	

15



Outcome Index Tracker

t^{III} Bristol Myers Squibb"



Outcome Capital Index Tracker (LTM)





99 High Street Suite 2900 Boston, MA 02110 (703) 225-1500



Reach the Right Outcome